Incyte Corporation (NASDAQ:INCY) proprietary therapeutics in oncology, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.75 per share.
For the full year, analysts predict revenues of $ 2537.31 million, while looking forward to loss of $ 0.06 per share.
Previous Quarter Performance
Incyte Corporation unveiled income for the second quarter of $ 1.24 per share, from the revenue of $ 688.04 million. The quarterly earnings swell 65.33 percent while revenues increased 38.22 percent compared with the same quarter last year.
Wall street analysts are predicting, INCY to report 2Q20 income of $ 0.88 per share from revenue of $ 612.14 million. The bottom line results beat street analysts by $ 0.36 or 40.91 percent, at the same time, top line results outshined analysts by $ 75.90 million or 12.40 percent.
Stock Performance
Shares of Incyte Corporation traded up $ 6.26 or 7.37 percent on Wednesday, reaching $ 91.21 with volume of 2.03 million shares. Incyte Corporation has traded high as $ 92.39 and has cracked $ 87.48 on the downward trend
The closing price of $ 91.21, representing a 35.96 % increase from the 52 week low of $ 62.48 and a 23.03 % decrease over the 52 week high of $ 110.37.
The company has a market capital of $ 19.95 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by Bank of America at Buy rating, with $ 110.00 target price.
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 103.00 target price.
Conference Call
Incyte Corporation will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.incyte.com
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis.
